Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: The optim study

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Romero Gómez, Manuel ^a   Turnes, Juan ^b   Ampuero, Javier ^a   Oyagüez, Itziar ^c   Cuenca, Beatriz ^d   Gonzalez Garcia, Juan ^e   Muñoz Molina, Belén ^f   Aguilar, Rocio ^g   Leal, Sandra ^g   Planas, Ramon ^h   Garcia Samaniego, Javier ^e   Diago, Moises ⁱ   Crespo, Javier ^j   Calleja, Jose Luis ^k   Casado, Miguel Angel ^c   Sola, Ricard ^l  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL MONTECELO   (Spain)

^c Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^d HOSPITAL INFANTA CRISTINA   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f Unidad de Hepatología Roche Farma   (Spain)

^g FISEVI   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^l INST MUNIC D INVESTIGACIO MEDICA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RIBAVIRIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION MAKING; DIAGNOSTIC ACCURACY; FEMALE; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PROSPECTIVE STUDY; RAPID VIROLOGICAL RESPONSE; RESPONSE VARIABLE; VALIDATION STUDY; VIRUS LOAD; CHEMISTRY; CLINICAL TRIAL; MIDDLE AGED; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84926393490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122613     Document Type: Article

References (26)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74. doi: 10.1002/hep.22759 PMID: 19330875
2. Thompson A, Devine S, Kattan M, Muir A. Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. PLoS One 2014; 9: e103370. doi: 10.1371/journal.pone.0103370 PMID: 25084272
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401. doi: 10.1038/nature08309 PMID: 19684573
4. Fernández-Rodríguez A, Rallón N, Berenguer J, Jiménez-Sousa MA, Cosín J, Guzmán-Fulgencio M, et al. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. AIDS 2013; 27: 163-73. doi: 10.1097/QAD.0b013e32835c11e8 PMID: 23135173
5. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B geno-type on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350. doi: 10.1016/j.cgh.2010.07.019 PMID: 20728570
6. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34: 297-305. doi: 10.1111/j.1365-2036.2011.04716.x PMID: 21623851
7. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013; 58: 479-87. doi: 10.1016/j.jhep.2012.11.020 PMID: 23183529
8. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206. doi: 10.1056/NEJMoa1010494 PMID: 21449783
9. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med 2009; 361: 580-93. doi: 10.1056/NEJMoa0808010 PMID: 19625712
10. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26. PMID: 12883497
11. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6. PMID: 17567829
12. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92. PMID: 12297848
13. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-373. PMID: 1808228
14. Oblikue Consulting Base de datos sanitarios eSalud. Available: http://www.oblikue.com/bddcostes/. Accessed 2013 May 10.
15. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al.; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16. doi: 10.1016/S0140-6736(10)60934-8 PMID: 20692693
16. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, et al. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol 2012; 56: 1276-82. doi: 10.1016/j.jhep.2011.12.026 PMID: 22314423
17. Martínez-Bauer E, Crespo J, Romero-Gómez M, Moreno-Otero R, Solá R, Tesei N, et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 2006; 43: 72-80. PMID: 16374857
18. Lindh M, Arnholm B, Eilard A, Färkkilä M, Hellstrand K, Lagging M, et al. Hepatitis C treatment response kinetics and impact of baseline predictors. J Viral Hepat 2011; 18: 400-7. doi: 10.1111/j.1365-2893.2010.01323.x PMID: 20500548
19. Araújo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, de Melo ES, et al. Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18: 52-60.
20. Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, Hou NJ, et al. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol 2010; 25: 758-65. doi: 10.1111/j.1440-1746.2009.06148.x PMID: 20492331
21. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al.; Nagano Interferon Treatment Research Group. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-60. doi: 10.1002/hep.22543 PMID: 18925643
22. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011; 6: e18322. doi: 10.1371/journal.pone.0018322 PMID: 21479134
23. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9. doi: 10.1053/j.gastro.2010.04.013 PMID: 20399780
24. Bichoupan K, Martel-Laferriere V, Ng M, Schonfeld E, et al. Real world costs of telaprevir-based triple therapy, including costs of managing adverse events, at the Mount Sinai Medical Center, NY: $195,000 per SVR12. Hepatology 2013; A244.
25. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16. doi: 10.1056/NEJMoa1012912 PMID: 21696307
26. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365: 1014-24. doi: 10.1056/NEJMoa1014463 PMID: 21916639